[go: up one dir, main page]

EA201001895A1 - PROCEDURES FOR EXCESSING AMINO ACIDS - Google Patents

PROCEDURES FOR EXCESSING AMINO ACIDS

Info

Publication number
EA201001895A1
EA201001895A1 EA201001895A EA201001895A EA201001895A1 EA 201001895 A1 EA201001895 A1 EA 201001895A1 EA 201001895 A EA201001895 A EA 201001895A EA 201001895 A EA201001895 A EA 201001895A EA 201001895 A1 EA201001895 A1 EA 201001895A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acids
excessing
procedures
compounds
relates
Prior art date
Application number
EA201001895A
Other languages
Russian (ru)
Inventor
Эрик Дэвид Мохер
Джеймс Аллен Монн
Консепсьон Педрегал-Терсеро
Хаиме Гонзало Бланко-Ургоити
Иван Колладо Кано
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201001895A1 publication Critical patent/EA201001895A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к синтетическим пролекарствам возбуждающих аминокислот формулы (I) и к способам их получения. Далее изобретение относится к применению данных соединений и фармацевтическим композициям, включающим данные соединения, для лечения неврологических расстройств и психиатрических расстройств.This invention relates to synthetic prodrugs of excitatory amino acids of the formula (I) and to methods for their preparation. The invention further relates to the use of these compounds and pharmaceutical compositions comprising these compounds for the treatment of neurological disorders and psychiatric disorders.

EA201001895A 2002-06-11 2003-06-06 PROCEDURES FOR EXCESSING AMINO ACIDS EA201001895A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02380121 2002-06-11
EP02380120 2002-06-11
US41593702P 2002-10-03 2002-10-03
US41593602P 2002-10-03 2002-10-03

Publications (1)

Publication Number Publication Date
EA201001895A1 true EA201001895A1 (en) 2011-06-30

Family

ID=43505959

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001895A EA201001895A1 (en) 2002-06-11 2003-06-06 PROCEDURES FOR EXCESSING AMINO ACIDS

Country Status (4)

Country Link
KR (2) KR20100129347A (en)
EA (1) EA201001895A1 (en)
PL (1) PL221526B1 (en)
TW (2) TW200833674A (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001617B1 (en) * 1995-11-16 2001-06-25 Эли Лилли Энд Компани Excitatory amino acid derivatives

Also Published As

Publication number Publication date
KR101061663B1 (en) 2011-09-01
PL390514A1 (en) 2005-10-17
PL221526B1 (en) 2016-04-29
TW200400815A (en) 2004-01-16
KR20100129347A (en) 2010-12-08
TWI315666B (en) 2009-10-11
TW200833674A (en) 2008-08-16
KR20050009742A (en) 2005-01-25

Similar Documents

Publication Publication Date Title
EA200801711A1 (en) PROCEDURES FOR EXCESSING AMINO ACIDS
EA200870127A1 (en) POLYCYCLIC DERIVATIVES OF AMINO ACIDS AND METHODS OF THEIR APPLICATION
EA200600294A1 (en) [1,8] NAFTYRIDIN-2-ONE AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA
EA200200716A1 (en) ARYL CONDENSED AZOPOLYCYCLIC COMPOUNDS
CY1107956T1 (en) USE OF 2-AMINOTETRALINE SUBSTITUTES FOR PREVENTIVE TREATMENT OF PARKINS DISEASE
BR0316350A (en) Diaminotriazoles useful as protein kinase inhibitors
SE0303180D0 (en) Novel compounds
SE0302232D0 (en) Novel Compounds
MX2007013216A (en) Substituted amide derivatives as protein kinase inhibitors.
PT1448564E (en) SUBSTITUTED INDOLIZIN TYPE COMPOUND AND METHODS OF USE
MXPA03011484A (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
SE0301373D0 (en) Novel compounds
EA200300942A1 (en) DERIVATIVES N- (ARYLSULPHONYL) BETA AMINO ACIDS CONTAINING A SUBSTITUTE AMINOMETHYL GROUP, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
ATE453636T1 (en) SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE
CY1107894T1 (en) GABA analogue prodrugs, their compositions and uses
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
EA200701296A1 (en) 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines
EA200401114A2 (en) SUBSTITUTED HYDROXYETHYLAMINES
BRPI0411673A (en) compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a compound
TW200502221A (en) Novel lactams and uses thereof
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EA200601607A1 (en) SULPHONAMIDE CONNECTIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
TW200504036A (en) Novel lactams and uses thereof
ATE399758T1 (en) DERIVATIVES OF 1-PHENYLALKANECARBONIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2002055481A8 (en) Prodrugs of excitatory amino acids